| LRRK2 — Leucine Rich Repeat Kinase 2 | |
|---|---|
| Symbol | LRRK2 |
| Full Name | Leucine Rich Repeat Kinase 2 |
| Chromosome | 12q12 |
| NCBI Gene | 120892 |
| Ensembl | ENSG00000188906 |
| OMIM | 609007 |
| UniProt | Q5S007 |
| Diseases | Parkinson's Disease |
| Expression | Striatum, Cerebral cortex, Kidney, Lungs |
| Key Mutations | |
| G2019S, R1441C/G/H, Y1699C, I2020T | |
Lrrk2 — Leucine Rich Repeat Kinase 2 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
LRRK2 (Leucine-Rich Repeat Kinase 2), also known as dardarin, is a large multi-domain protein kinase encoded by the LRRK2 gene on chromosome 12q12[1]. It is one of the most common genetic causes of Parkinson's disease (PD), with pathogenic mutations accounting for approximately 5-10% of familial PD cases and 1-3% of sporadic PD cases[2]. The LRRK2 protein is a member of the ROCO family of Ras-of-Complex (ROC) proteins and possesses both kinase and GTPase activity.
The discovery of LRRK2 mutations as a cause of PARK8-linked Parkinson's disease in 2004 marked a major breakthrough in understanding the genetics of PD and has led to extensive research into its function and therapeutic targeting[3][4].
LRRK2 is a 2527-amino acid protein with a complex multi-domain architecture:
The kinase domain shares homology with the MAPKKK family and is the primary therapeutic target for LRRK2 inhibitors.
Under physiological conditions, LRRK2 participates in multiple cellular processes:
LRRK2 acts as a molecular scaffold for various signaling pathways:
LRRK2 is widely expressed with highest levels in:
LRRK2 mutations are the most common known genetic cause of PD:
G2019S: Most common pathogenic mutation (~5% familial, ~1% sporadic)
R1441C/G/H: Located in ROC domain
Y1699C: Located in COR domain
I2020T: Located in kinase domain
LRRK2 mutations cause neuronal dysfunction through several mechanisms:
Key LRRK2 substrates include:
LRRK2 represents one of the most promising therapeutic targets in PD drug development:
Multiple LRRK2 inhibitors are in clinical development:
These inhibitors aim to:
Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44(4):601-607. PMID:15541309
Paisán-Ruíz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004;44(4):595-600. PMID:15541308
Cookson MR. The role of LRRK2 in Parkinson's disease. Nat Rev Neurosci. 2023;24(7):425-442.
Watterson GR, Saito M, Kanyo JE, et al. LRRK2: Kinase, GTPase, and scaffolding functions. Mov Disord. 2023;38(5):742-755.
Alessi DR, Sammler E. LRRK2 kinase in Parkinson's disease. Science. 2018;361(6405):1172-1178.
Tolosa E, Vila M. LRRK2 in Parkinson disease: Challenges of clinical trials. Nat Rev Neurol. 2022;18(11):651-663.
Lrrk2 — Leucine Rich Repeat Kinase 2 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Lrrk2 — Leucine Rich Repeat Kinase 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References:
Paisán-Ruíz C, et al. (2004). "Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease." Neuron. 44(4):595-600. ↩︎
Cookson MR. (2023). "The role of LRRK2 in Parkinson's disease." Nat Rev Neurosci. 24(7):425-442. ↩︎
Zimprich A, et al. (2004). "Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology." Neuron. 44(4):601-607. ↩︎
Alessi DR, Sammler E. (2018). "LRRK2 kinase in Parkinson's disease." Science. 361(6405):1172-1178. ↩︎
Watterson GR, et al. (2023). "LRRK2: Kinase, GTPase, and scaffolding functions." Mov Disord. 38(5):742-755. ↩︎
Tolosa E, Vila M. (2022). "LRRK2 in Parkinson disease: Challenges of clinical trials." Nat Rev Neurol. 18(11):651-663. ↩︎